Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 8/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966598 | 1.00 | AR (0.44) | ARCFTRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2974518 | 1.00 | AR (0.44) | ARCFTRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2978964 | 0.94 | AR (0.45) | ARCFTRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2970553 | 0.94 | AR (0.45) | ARCFTRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2970548 | 0.94 | AR (0.45) | ARCFTRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2979525 | 0.88 | CFTR (0.45) | ARCFTRWDR5 | |
| SCHEMBL2977966 | 0.88 | CFTR (0.45) | ARCFTRWDR5 | |
| SCHEMBL2974964 | 0.88 | CFTR (0.45) | ARCFTRWDR5 | |
| SCHEMBL2974566 | 0.88 | CFTR (0.56) | ARCFTR | |
| SCHEMBL2974570 | 0.88 | CFTR (0.56) | ARCFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802700-B2 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-12 | — | — | US | claimed |
| US-8614327-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-24 | — | — | US | claimed |
| US-20130165442-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-27 | — | — | US | claimed |
| US-20120309758-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | claimed |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | claimed |
| US-20140343098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-20 | — | — | US | disclosed |
| US-8802700-B2 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-12 | — | — | US | disclosed |
| US-8614327-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130165442-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-27 | — | — | US | disclosed |
| US-8354427-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120309758-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165442-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | AR 3016/4885CFTR 1/4885KDM4E 4262/4885 |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | AR 3016/4885CFTR 1/4885KDM4E 4262/4885 |
| US-20140343098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | AR 3016/4885CFTR 1/4885KDM4E 4262/4885 |
| US-20120309758-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | AR 3016/4885CFTR 1/4885KDM4E 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.